SRR12475104
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.530
- INTERFERON_GAMMA_RESPONSE+0.490
- ALLOGRAFT_REJECTION+0.440
- MYC_TARGETS_V2+0.340
- E2F_TARGETS+0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.310
- G2M_CHECKPOINT+0.290
- DNA_REPAIR+0.270
- IL6_JAK_STAT3_SIGNALING+0.220
- TNFA_SIGNALING_VIA_NFKB+0.220
Top 10 suppressed
- ANGIOGENESIS-0.400
- PROTEIN_SECRETION-0.350
- UV_RESPONSE_DN-0.300
- BILE_ACID_METABOLISM-0.290
- CHOLESTEROL_HOMEOSTASIS-0.280
- WNT_BETA_CATENIN_SIGNALING-0.250
- ANDROGEN_RESPONSE-0.240
- FATTY_ACID_METABOLISM-0.240
- NOTCH_SIGNALING-0.240
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 695836ff-c54b-47bf-8a29-5224811afa7e | — | — | 0.856 |
| 2 | TCGA-AC-A6IW-01A-12R-A33J-07 | — | E | 0.838 |
| 3 | c63f3f74-14fa-4a9e-9925-30b0f5da7dd9 | — | — | 0.836 |
| 4 | c4779698-5c81-4eed-80ac-80fdd47f658b | — | — | 0.819 |
| 5 | TCGA-OL-A5D7-01A-11R-A27Q-07 | — | E | 0.816 |
| 6 | MNG921 | — | — | 0.813 |
| 7 | SRR12475171 | — | — | 0.803 |
| 8 | MBCproject_0095_T3_RNA | — | E | 0.803 |
| 9 | TCGA-C8-A134-01A-11R-A115-07 | — | E | 0.800 |
| 10 | SRR8613746 | — | D | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.220 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.090 | Idelalisib | — uncovered |
| MYOGENESIS | 0.090 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |